/PRNewswire/ The global induced pluripotent stem cells production market size is estimated to reach USD 1.76 billion by 2028, registering a CAGR of 8.0%.
Evotec AG: Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure
RISK-REWARD-SHARING PARTNERSHIP LEVERAGES COMPLEMENTARY PLATFORMS
HAMBURG, GERMANY / ACCESSWIRE / February 4, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf ( UKE ) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure.
Under the terms of the partnership, Evotec and UKE will leverage their complementary strengths for the development of a new cell therapy approach using Engineered Heart Tissue for the treatment of heart failure. Heart failure is frequently associated with ischemic heart disease and often comes with a poor prognosis. Mortality is comparable to that of the most common cancers, with